Stockreport
Incyte: An Undervalued Healthcare Gem [Seeking Alpha]
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
Jakafi delivered $3.09B in 2025 sales, up 11% YoY, underpinning strong operational performance and funding for R&D. Opzelura posted 33% YoY growth with $678M in 2025 sales, highlighting successful portfolio expansion. Broader business segments achieved 121% YoY growth, demonstrating effective execution across multiple therapeutic areas. Tom Werner/DigitalVision via Getty Images Investment Thesis Incyte ( INCY ) is a global biopharmaceutical company that discovers, develops, and sells proprietary therapeutics. Incyte is a strong investment option for investors who are looking for an undervalued gem in the health care sector. Thanks This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of INCY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with a
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | INCY | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
INCY alerts
INCY alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
NEWS
NEWS
- Incyte (INCY) had its price target lowered by UBS Group AG from $104.00 to $94.00. They now have a "neutral" rating on the stock.[MarketBeat]
- Incyte Announces Executive Leadership Appointments[Business Wire]
- Incyte (INCY) had its "buy" rating reaffirmed by HC Wainwright. They now have a $135.00 price target on the stock.[MarketBeat]
- Incyte (INCY) had its "overweight" rating reaffirmed by Barclays PLC.[MarketBeat]
- Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting[Business Wire]
- More
INCY
SEC Filings
SEC Filings
- 3/26/26 - Form 4
- 3/26/26 - Form 8-K
- 3/19/26 - Form 4
- INCY's page on the SEC website
- More